Last mentioned: Mar 4, 2026
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Investor Briefings
Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
Global License Agreement
Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.